imatinib + panobinostat

This is a combination therapy consisting of two small molecule drugs—imatinib and panobinostat (also known as LBH589). Imatinib is a tyrosine kinase inhibitor that targets BCR-ABL, platelet-derived growth factor receptor (PDGFR), and c-KIT kinases. It disrupts signaling pathways critical for the proliferation and survival of certain cancer cells. Panobinostat (LBH589) is a non-selective histone deacetylase inhibitor (HDACi) that modulates gene expression by inhibiting multiple HDAC enzymes across class I, II, and IV. This leads to epigenetic changes resulting in cell cycle arrest or apoptosis in malignant cells. The combination has been investigated for synergistic antitumor effects in cancers such as chordoma and other malignancies where both kinase signaling and epigenetic regulation are implicated[1][3][4].

Brand names

Gleevec + Farydak

Other names

imatinib mesylate + panobinostatGlivec + FarydakImkeldi + Farydak